Riskpilot← Back to searchSign inGet full accessNew Normal Labs ApS
APSActiveCVR 39733560Vestre Teglværksvej 7Sports and recreation education · NACE 8551Est. 2018— employeeswww.newnormallabs.com
Revenue 2024
—
EBITDA margin
—
+60% vs 2023
Equity ratio
4.5%
Financial strength
Net profit 2024
DKK -7K
+60% vs 2023
| Revenue | — | — |
| EBITDA | DKK -7K | +60% |
| Net profit | DKK -7K | +60% |
| Total assets | DKK 257K | -1% |
| Equity | DKK 12K | -38% |
| Employees | — | — |
Legal name
New Normal Labs ApS
CVR number
39733560
Legal form
Anpartsselskab
NACE code
8551 · Sports and recreation education
Founded
16. juli 2018
Share capital
DKK 40.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en direktør alene
Company purpose
Virksomhedens formål er at coache individer og teams opnå deres mål, igennem data-understøttede værktøjer til optimal ernærring, træning, mental optimering.
Virksomheden har gennem udvidet adgang til et bredt internationalt Biohacking netværk, mulighed for at inddrage den seneste viden samt eksperter, til at understøtte alle facetter af rejsen imod en ny "norm" for individet eller teamet.
Address
Vestre Teglværksvej 7
Phone
+4551582908
Email
hi@newnormallabs.com
Website
www.newnormallabs.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | -23 | — | -19 | 33 | -17 | — |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -23 | 6 | -19 | 33 | -17 | -7 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -23 | 6 | -19 | 33 | -17 | -7 |
| Net financials | 0 | 0 | -0 | -0 | -0 | -0 |
| Profit before tax | -23 | 6 | -20 | 32 | -18 | -7 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | -23 | 6 | -20 | 32 | -18 | -7 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 1 | 19 | 64 | 65 | 260 | 257 |
| Equity | -23 | -17 | 4 | 36 | 19 | 12 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 24 | 36 | 60 | 29 | 241 | 245 |
| Total debt | 24 | 36 | 60 | 29 | 241 | 245 |
EBITDA margin
-700400.0%
This company
15.8%
Market median
-4433011% vs market
20192024
Equity ratio
4.5%
This company
38.2%
Market median
-88% vs market
20192024
Return on equity
-60.2%
This company
18.4%
Market median
-427% vs market
20192024
Net profit margin
-702200.0%
This company
8.1%
Market median
-8669236% vs market
20192024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20192024
Debt / equity
21.02×
This company
0.62×
Market median
-3290% vs market
20192024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2018-07-16 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MK Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
New Normal Labs ApS 
Biowatch Holding ApSBoard members of New Normal Labs ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Martin Kremmer | Chief Executive Officer | 0 companies |